Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 78.02 USD | -1.69% | +1.85% | -9.12% | |
| Dec. 06 | Transgene: new CFO, share price rises | CF |
| Dec. 04 | IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
78.05USD
Average target price
90.39USD
Spread / Average Target
+15.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.12% | 98 886 M $ | |
| +60.80% | 530 B $ | |
| +42.05% | 438 B $ | |
| -12.03% | 377 B $ | |
| -6.37% | 268 B $ | |
| -8.44% | 258 B $ | |
| -14.13% | 230 B $ | |
| +0.79% | 200 B $ | |
| -9.98% | 198 B $ | |
| -44.13% | 163 B $ |
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- News Gilead Sciences, Inc.
- UBS Adjusts Gilead Sciences Price Target to $90 From $85, Maintains Neutral Rating
